Letters
Semaglutide and risk of major cardiovascular events
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
BMJ 2024; 384 doi: https://doi.org/10.1136/bmj.q53 (Published 15 January 2024) Cite this as: BMJ 2024;384:q53Article usage
Article metrics provide readers and authors with an indication of how often a specific article has been accessed month by month. It counts three formats - abstract/extract, full text and pdf. The page is updated each day.